Conviction
$ Value
$10.8M
Shares
3,387,529
Price
$3
Filed
Aug 4
▶ Why this score? (10/10)
- ✓ Open market buy (+3)
- ✓ Trade value >= $5.0M (+3)
- ✓ % of holdings >= 20% (+2)
- ✓ Director (+1)
- ✓ 10%+ owner (+1)
- ✓ Not a 10b5-1 plan (+1)
Insider
Name
Flynn James E
Title
—
CIK
0001352546
Roles
Transaction Details
Transaction Date
2025-07-31
Code
P
Table
Non-Derivative
Ownership
Indirect
Equity Swap
No
Shares After
9,538,918
Footnotes
This Form 4 is being filed by the undersigned as well as the entities listed on the Joint Filer Information Statement attached as an exhibit hereto (the "Reporting Persons"). Deerfield Mgmt III, L.P. is the general partner of Deerfield Private Design Fund III, L.P. ("Fund III"). Deerfield Mgmt IV, L.P. is the general partner of Deerfield Private Design Fund IV, L.P. ("Fund IV"). Deerfield Mgmt HIF, L.P. is the general partner of Deerfield Healthcare Innovations Fund, L.P. ("Deerfield HIF"). Deerfield Mgmt, L.P. is the general partner of Deerfield Partners, L.P. ("Deerfield Partners"). Deerfield Management Company, L.P. is the investment manager of Deerfield Partners, L.P., Fund III, Fund IV and Deerfield HIF (collectively, the "Funds"). James E. Flynn is the sole manager of the general partner of each of Deerfield Mgmt III, L.P., Deerfield Mgmt IV, L.P., Deerfield Mgmt HIF, L.P., Deerfield Mgmt, L.P. and Deerfield Management Company, L.P. | In accordance with Instruction 4 (b)(iv) to Form 4, the entire amount of the Issuer's securities held by the Funds is reported herein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
Filing Info
Flynn James E's History
| Date | Ticker | Type | Value |
|---|---|---|---|
| 2025-11-24 | NUVL | ▼ | $35.4M |
| 2025-11-24 | NUVL | ▼ | $35.4M |
| 2025-07-31 | LRMR | ▲ | $10.8M |
| 2025-07-31 | LRMR | ▲ | $10.8M ★ |
| 2025-07-31 | LRMR | ▲ | $8.3M |
| 2025-06-27 | SPRY | ▼ | $6.8M |
| 2025-06-27 | SPRY | ▼ | $6.8M |
| 2025-06-18 | NUVL | A | $0 |
| 2025-06-18 | NUVL | A | $0 |
| 2025-06-18 | NUVL | A | $0 |
Other Insiders at LRMR (90d)
| Insider | Bought | Sold | Last |
|---|---|---|---|
|
Celano Michael
Chief Financial Officer
|
— | — | 2026-01-26 |
|
BEN-MAIMON CAROLE
President and CEO
|
— | — | 2026-01-26 |
|
Clayton Russell
Chief Medical Officer
|
— | — | 2026-01-26 |
|
Shankar Gopi
Chief Development Officer
|
— | — | 2026-01-26 |